Welcome to our dedicated page for Option Care Health SEC filings (Ticker: OPCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Option Care Health, Inc. filings document the public-company disclosures of a Nasdaq-listed provider of home and alternate-site infusion services. Its common stock is registered under the symbol OPCH, and its regulatory record includes Current Reports on Form 8-K, proxy materials, and exhibits tied to operating results and corporate actions.
OPCH filings cover quarterly and annual financial results, non-GAAP measure reconciliations, Regulation FD investor presentations, amendments to its first lien credit agreement, executive officer changes and related severance matters, and definitive proxy disclosures. The proxy record addresses board governance, stockholder voting matters, executive compensation, and capital allocation context for the company's infusion services business.
Option Care Health, Inc. furnished an investor presentation in connection with its participation in the Bank of America Health Care Conference. The presentation describes the company as a leading independent provider of home and alternate site infusion services.
Option Care Health reports serving over 315,000 patients in 2025 through more than 5,000 multidisciplinary clinicians, 190+ U.S. locations, about 90 full-service pharmacies, 750+ infusion chairs, and in-network status with the top 10 payers covering 96% of insured lives. For 2026, management highlights priorities that include taking actions to reaccelerate its revenue growth trajectory, reprioritizing capital allocation toward internal investments for profitable growth and share repurchases, and rebuilding momentum through coverage, conversion, and enhanced service levels.
Option Care Health, Inc. director Timothy P. Sullivan reported an open-market purchase of common stock. He bought 24,154 shares of Option Care Health at a weighted average price of $20.6869 per share, through multiple transactions with prices ranging from $20.47 to $20.69. Following these purchases, he directly owns 73,383 shares of the company’s common stock.
Option Care Health Inc. reports FMR LLC beneficial ownership of 6,426,119.18 shares of Common Stock, representing 4.1%. The Schedule 13G/A (Amendment No. 1) shows FMR LLC as filer and names Abigail P. Johnson with dispositive authority; the filing cites Exhibit 99 and a power of attorney effective April 13, 2026.
Option Care Health, Inc. director Harry M. Jansen Kraemer Jr. reported an open-market purchase of 36,610 shares of Common Stock on May 4, 2026. The shares were bought at a weighted average price of $21.4087 per share, with individual trade prices ranging from $21.35 to $21.475. Following this purchase, he directly owns 450,000 shares of Option Care Health, Inc.
Option Care Health, Inc. announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer, effective May 8, 2026. The company states that Mr. Grashoff will receive separation benefits under its Amended and Restated Executive Severance Plan, subject to a general release of claims in favor of the company and his continued compliance with existing restrictive covenants.
Option Care Health, Inc. Chief Financial Officer Meenal Sethna bought 16,225 shares of common stock in an open-market purchase on May 4, 2026 at a weighted average price of $20.1587 per share.
The filing notes these shares were acquired through multiple trades at prices ranging from $19.94 to $20.38 per share. Following the transaction, Sethna directly owns 98,337 shares of Option Care Health common stock.
Option Care Health, Inc. Chief Executive Officer John Charles Rademacher reported an open-market purchase of 12,500 shares of common stock on May 4, 2026 at a weighted average price of $21.1765 per share. Following this transaction, he directly owns 695,152 common shares.
The shares were bought in multiple trades that day at prices ranging from $21.14 to $21.18 per share, indicating a modest incremental increase to his existing equity stake in the company.
Option Care Health reported steady Q1 2026 results, with net revenue of $1,350.7M, up slightly from $1,333.0M a year earlier. Net income was $45.3M versus $46.7M and diluted EPS rose to $0.29 from $0.28 as the share count declined.
Gross profit edged down to $262.0M and margin slipped to 19.4%, as strength in acute therapies was offset by pressure in chronic inflammatory disease treatments. Management now expects chronic inflammatory disease dynamics to reduce 2026 gross profit by about $55M.
The company ended the quarter with $177.3M in cash and expanded its revolving credit facility to $850.0M, leaving $846.0M available. It also repurchased 528,981 shares for $17.5M, with $675.0M remaining under its $1.0B authorization.
Vanguard Capital Management reports beneficial ownership of 8,228,614 shares (5.25%) of Option Care Health Inc common stock as of 03/31/2026. The filing states Vanguard has sole dispositive power over 8,228,614 shares and sole voting power for 1,212,291 shares. The disclosure notes these holdings include securities held for Vanguard funds and certain managed accounts and lists affiliated Vanguard entities that exercise voting or dispositive power.
Option Care Health reported mixed first quarter 2026 results, with net revenue of $1,350.7 million, up 1.3% year over year. GAAP net income was $45.3 million, down 3.0%, while GAAP diluted EPS rose to $0.29 and Adjusted diluted EPS held flat at $0.40.
Adjusted EBITDA was $104.8 million, down 6.3%, and operating activities used $12.1 million of cash. The company repurchased $17.5 million of stock and expanded its revolving credit facility from $400 million to $850 million, adding financial flexibility.
For full year 2026, Option Care Health now guides to net revenue of $5.675–$5.775 billion, Adjusted EBITDA of $480–$505 million, Adjusted diluted EPS of $1.82–$1.92, and at least $320 million of cash provided by operating activities, reflecting modest growth expectations.